% | $
Quotes you view appear here for quick access.

Zalicus AŞ Message Board

  • want2movesouth want2movesouth May 2, 2013 12:19 PM Flag

    2 Biotechs Primed For Prosperity In 2013

    Zalicus CEO has stated that potential partners are knocking on the door anxiously waiting for positive Z160 data. A Z160 partnership would provide the company with a substantial influx of cash and royalties etc. The company reported cash of 36.4 million as of December 2012. That should easily carry them into 2014 without any additional fundraising. At the current stock price of .58 and a market cap of 74 million, shares are trading at a fraction of the potential value of Z160. This catalyst is likely going to be one of the biotech sector's most followed clinical study data releases in 2013. The market potential for Z160 is difficult to assess, but according to Jason Napodano, conservative estimates of 500-750m and potential of over 2 billion, based on Pfizer's (PFE) current sales of Neurontin. The potential for a non-addictive pain medication with powerful efficacy, makes Z160 a game changing medication in the pain market. I expect the stock price to exceed $1 and potentially run up to 1.50 prior to the release of data in the 4th quarter. For investors planning on holding through the data release, positive results will likely send the stock into the $3 to $5 range. If the contract with Novartis is not renewed the stock price will suffer in the near term but ultimately any negative news on the company will be dwarfed by the run up to Z-160 data release.

    SortNewest  |  Oldest  |  Most Replied Expand all replies